Areas reviewed: In vivo tumor models, oncogenes and tumor suppressor genes in vivo, gene target validation, drug efficacy testing, human genetics/genomics, pharmacogenetics, pharmacogenomics, genetic risk, genotype to phenotype, gene therapy testing, and biomarker identification/development.

Scott A. Oakes, MD, Chair
University of California, San Francisco
San Francisco, CA

Ralph Scully, MD, PhD, Vice Chair
Beth Israel Deaconess
Boston, MA

Ron Bose, MD, PhD
Washington University
St. Louis, MO

Jonathan Brody, PhD
Thomas Jefferson University
Philadelphia, PA

Mark Chiang, MD, PhD
University of Michigan
Ann Arbor, MI

Ramana Davuluri, PhD
The Wistar Institute
Philadelphia, PA

Nancy Gargano, Stakeholder
Stevensville, MI

Rani E. George, MD, PhD, MRCP
Dana-Farber Cancer Institute
Boston, MA

Scott Gerber, PhD
Dartmouth-Hitchcock Geisel School of Medicine
Lebanon, New Hampshire

Steven Grossman, MD, PhD
Virginia Commonwealth University
Richmond, VA

Amir A. Jazaeri, MD
University of Virginia
Charlottesville, VA

David Kirsch, MD, PhD
Duke University Medical Center
Durham, NC

W. Kimryn Rathmell, MD, PhD
University of North Carolina
Chapel Hill, NC

Marilyn Rex, Stakeholder
San Mateo, CA

Kristy L. Richards, MD, PhD
University of North Carolina
Chapel Hill, NC

Alejandro Sweet-Cordero, MD
Stanford University
Stanford, CA

Amanda Toland, PhD
The Ohio State University
Columbus, OH

Kathryn Wikenheiser-Brokamp, MD, PhD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH